ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTNM vs ARCT // NET PROFIT MARGIN

Contineum Therapeutics Inc. (Class A) (NASDAQ) VS. Arcturus Therapeutics Holdings Inc. (NASDAQ) • 15-METRIC TALLY: CTNM 3 — ARCT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTNM VS. ARCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTNM ARCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -29.00% -35.00% +6.00 CTNM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -15.82% -21.57% +5.75 CTNM /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -46.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.25 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.0 44.5 -1.50 ARCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $351.0M $345.3M $5.7M CTNM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTNM REV ARCT REV CTNM GROSS % ARCT GROSS % CTNM FCF ARCT FCF
FY 2025 $0 $82.0M — — -$55.5M -$74.5M
FY 2024 $0 $152.3M — — -$33.4M -$60.4M
FY 2023 $50.0M $166.8M — — $19.3M -$18.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTNM // BETA —
ARCT // BETA —